Daniel D. Karp
The University of Texas MD Anderson Cancer Center · 515 works · 18,999 citations · h-index 56
Top works
- Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
- Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer
- Prevention of Second Primary Tumors with Isotretinoin in Squamous-Cell Carcinoma of the Head and Neck
- Effect of Selenium and Vitamin E on Risk of Prostate Cancer and Other Cancers
- A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal Cancer
- Phase II Study of Taxol, Merbarone, and Piroxantrone in Stage IV Non-Small-Cell Lung Cancer: The Eastern Cooperative Oncology Group Results
- Vitamin E and the Risk of Prostate Cancer
- An Association between the Risk of Cancer and Mutations in the HRAS1 Minisatellite Locus
- 72 Multicenter trial of docetaxel (Taxotere) in platinum-treated non-small cell lung cancer (NSCLC): Confirmation of prolonged survival
- Elevated Plasma von Willebrand Factor Levels and Arterial Occlusive Complications Associated with Cisplatin-Based Chemotherapy
- Larynx Preservation Using Induction Chemotherapy plus Radiation Therapy as an Alternative to Laryngectomy in Advanced Head and Neck Cancer A Long-Term Follow-up Report
- Differentiation patterns in the blastic phase of chronic myeloid leukemia.
- Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) Results of Protocol E1293
- Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT)
- N2 lung cancer: Outcome in patients with false-negative computed tomographic scans of the chest
- Targeting RET in Patients With RET -Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
- Activity of Docetaxel in Platinum-Treated Non–Small-Cell Lung Cancer: Results of a Phase II Multicenter Trial
- Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study
- Randomized Phase III Intergroup Trial of Isotretinoin to Prevent Second Primary Tumors in Stage I Non-Small-Cell Lung Cancer
- Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer